Navigation Links
GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Date:3/10/2008

ed at: SGO's Annual Meeting on Women's Cancer. March 10, 2008

Tampa Convention Center.

(2) Wieting S., et al. HPV-013 Month 18 Extension Abstract. Presented at

the European Society of Paediatric Infectious Diseases (ESPID) annual

meeting on 2-4 May 2007

(3) GSK Data on File

(4) Schuind A. HPV-007 Final Analysis. To be presented at: SGO's Annual

Meeting on Women's Cancer. March 10, 2008

(5) Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for

squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix

compared to women with normal cytology in The Netherlands. Br J

Cancer. 2006;94:171-175.

(6) Liu S, Semenciw R, et al. Cervical cancer: the increasing incidence

of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ

2001; 164: 1151-1152.

(7) Harper DM, Franco EL et al. Sustained efficacy up to 4.5 years of a

bivalent L1 virus-like particle vaccine against human papillomavirus

types 16 and 18: follow-up from aluminium control trial. The Lancet

2006; 367: 1247-1255.

(8) Gall, S., et al. Sustained Efficacy up to 5.5 years in women

vaccinated with an AS04 Adjuvanted HPV 16/18 L1 VLP Vaccine.

Presented at AACR Medical Meeting. April 17, 2007

(9) Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic

cervical human papillomavirus infection. Infect Dis Clin North Am,

2005; 19:439-458

(10) Munoz N, Bosch FX, de Sanjose S,et al. Epidemiologic classification

of human papillomavirus types associated with cervical cancer. N Engl

J Med 2003; 348: 518-527

(11) Munoz N, Bosch FX, Castellsague X et al. Against which human

papillomavirus types shall we vaccinate and screen? The international

perspective. Int. J. Cancer 2004; 111; 278-285

(1
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
3. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
7. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
8. Thomson Healthcare Cancer Profiler Used in Study
9. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
10. CMC, Moffitt Partner to Study Cancer
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
... N.Y., Dec. 22 Cold Spring Publishing, LLC, announced ... change to Harborside Press, LLC. , In addition, Harborside Press ... over the past year requires a substantial expansion in personnel and ... the new offices of Harborside Press will be located at 37 ...
... , JACKSON, Miss., Dec. 22, 2009 University of ... VISICU e ICU® Program to enhance care of the critically ... in the region to implement the eICU Program, UMHC will serve ... UMHC is using the Philips VISICU eICU Program and ...
Cached Medicine Technology:University of Mississippi Health Care Implements Philips VISICU eICU(R) Program 2University of Mississippi Health Care Implements Philips VISICU eICU(R) Program 3
(Date:5/21/2013)... Spring is the perfect time to get ... with whole foods to weather perfect for outdoor exercise. ... the nutrition experts at Brilliant Nutrition highlight five spring ... 1. Eating Locally, With the abundance of fresh farmers' ... explore, spring is a great time to take advantage ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Standard advice ... test-drive and little else. However given industry’s less than ... to shoppers via the internet, Consumer Mattress Reports sets ... “ Choosing The Best Mattress .” , This article ... tips and suggestions that may not be readily apparent ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Patients of Dr. ... who have lost teeth due to gum disease and would ... for gum disease treatment with laser gum surgery. ... have the highest success rate out of all tooth replacement ... is a relatively new procedure cleared by the Food and ...
(Date:5/21/2013)... BOSTON (May 21, 2013) Prostaglandin analogues (PGAs), drugs ... of treatment for people with glaucoma, but their use ... with blurred vision, dryness, changes in eye color and ... that these drugs also cause upper and lower eyelid ... The findings are described in PLOS ONE . ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 HealthSmart continues ... expanding national presence has required the hiring of new ... HealthSmart is pleased to announce that Dawn Powell has ... serving as the Director of Account Management in the ... offices in Irving, Texas. With extensive client management, employee ...
Breaking Medicine News(10 mins):Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:Glaucoma drug can cause droopy eyelids 2Health News:New Talent Joins the HealthSmart Account Management Team 2
... finds 12-month course of valganciclover wards off ... News) -- Extended antiviral treatment after a lung ... rejection, a new study from Duke University Medical ... in lung transplant recipients is cytomegalovirus (CMV), which ...
... the potentially powerful influence of political pressure on ... that use of a largely unproven mammography screening ... cost. Joshua Fenton, assistant professor in the ... with colleagues from the University of Washington and ...
... to new targets, treatments, researcher says , MONDAY, June 14 ... new regions of the human genome that may be related ... in the June issue of the Archives of ... at risk for the devastating dementia just yet, however. , ...
... around 200,000 people in Sweden have been diagnosed with ... be helped by mechanical heart pumps, reveals a thesis ... a total of 99 patients with life-threatening heart failure ... long-term circulatory support., "Two-thirds of these patients survived," says ...
... Men with this history are more prone to hit and ... -- Men who attempted suicide before age 18 are much ... a study from the Oregon Social Learning Center in Eugene. ... neighborhoods who were assessed annually from ages 10 to 32. ...
... According ... within 6 months. Amgen’s Prolia is the newest product to enter the market. Prolia ... ... to a recent analysis by SDI , a leading healthcare market insight and analytics ...
Cached Medicine News:Health News:Longer Antiviral Therapy Reduces Lung Transplant Complications 2Health News:Use of unproven mammography tool soars with Medicare coverage 2Health News:Scientists Spot More Genes Related to Alzheimer's 2Health News:Teen Boys Who Attempt Suicide More Likely to Abuse as Adults 2Health News:SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option 2
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: